A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.

Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating ofa Sost antagonist are also disclosed, as it a method ofincreasing bone density by administering to a mammalian patient a therapeutic amount ofa Sost antagonist together with an antiresorptive drug.

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

The present specification relates to (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (AZD4017), or a pharmaceutically acceptable salt thereof, for oral use in the treatment or prophylaxis of wounds, for example in diabetic patients. Methods of treatment and prophylaxis and the use of the compound in the preparation of a medicament for the treatment and prophylaxis of wounds are also provided. ##STR00001##

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.

Methods and compositions are provided for the regeneration of articular cartilage by activating skeletal stem cells with a combination of (i) mechanical and (ii) biochemical stimulus. The mechanical stimulus can be an acute local injury. The biochemical stimulus can be a combination of an effective dose of a BMP2 activating agent and a VEGF inhibitor.

Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided.

A photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient is disclosed herein. In one embodiment, a treatment laser is applied to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition. The application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.